CLINICAL_TRIALS
ClinicalTrials.gov record update
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03213652
- Title field or adapter rule
- {'original_value': 'NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations', 'source_field': 'protocolSection.identificationModule.officialTitle'}
- Ingested At
- 2026-11-01T01:03:15.876540+00:00
- Published At
- 2026-10-06T00:00:00+00:00
- Record Updated At
- 2026-10-28
- Results Posted At
- 2026-10-06
- Source Retrieved At
- 2026-11-01T01:03:15.424322+00:00
- Timestamp Basis
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
- Date limitation
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Malignant Solid Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Wilms Tumor"]- protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-28", "type": "ACTUAL"}- protocolSection.identificationModule.nctId
"NCT03213652"- protocolSection.identificationModule.officialTitle
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct
{"date": "2026-10-06", "type": "ACTUAL"}
Study condition terms
Interventions recorded in this study
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo blood sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo a bone marrow aspiration and/or biopsy', 'name': 'Bone Marrow Aspiration and Biopsy', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo a bone scan', 'name': 'Bone Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo a CT scan', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Given PO', 'name': 'Ensartinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Correlative studies', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Correlative studies', 'name': 'Pharmacological Study', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo a PET scan', 'name': 'Positron Emission Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo radionuclide imaging', 'name': 'Radionuclide Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (ensartinib)'], 'description': 'Undergo an x-ray', 'name': 'X-Ray Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
An intervention appearing in a study record does not establish an effect or an approved use.
Drug names recorded in this source
A recorded drug name is not by itself an indication or a condition-specific relationship.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.